Literature DB >> 8334619

Epidemiology of intracranial meningioma.

W T Longstreth1, L K Dennis, V M McGuire, M T Drangsholt, T D Koepsell.   

Abstract

Intracranial meningiomas arise from the meninges and typically have benign histologic findings. They constitute approximately 20% of all intracranial tumors. Their incidence increases with age, and they affect women more commonly than men. The annual incidence per 100,000 people ranges from two to seven for women and from one to five for men. Since the first study was published in 1970, only eight major epidemiologic studies have been done that attempted to identify risk factors for meningioma. Ionizing radiation and head trauma have emerged as the most promising etiologic risk factors. In these studies, radiation doses as low as 1-2 Gy have been associated with increased risk. The role of dental radiographs has been suggested in some studies but not supported in others. An explanation for the apparent excess of meningiomas in women remains obscure. The potential effects of endogenous or exogenous sex hormones on tumor induction or growth remain unexplored in epidemiologic studies. More should be learned about the risk factors for meningioma in search of opportunities for prevention.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334619     DOI: 10.1002/1097-0142(19930801)72:3<639::aid-cncr2820720304>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  59 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  Stereotactic radiosurgery for benign meningiomas.

Authors:  Orin Bloch; Gurvinder Kaur; Brian J Jian; Andrew T Parsa; Igor J Barani
Journal:  J Neurooncol       Date:  2011-10-18       Impact factor: 4.130

3.  Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act.

Authors:  Therese A Dolecek; Emily Van Meter Dressler; Jigisha P Thakkar; Meng Liu; Abeer Al-Qaisi; John L Villano
Journal:  Cancer       Date:  2015-04-14       Impact factor: 6.860

4.  Demographic profile of patients diagnosed with intracranial meningiomas in two academic hospitals in Johannesburg, South Africa: a 12-month prospective study.

Authors:  Kaunda Ibebuike; John Ouma
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 5.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 6.  Radiotherapy of other sellar lesions.

Authors:  N Karavitaki
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 7.  Meningiomas among intracranial neoplasms in Johannesburg, South Africa: prevalence, clinical observations and review of the literature.

Authors:  K Ibebuike; J Ouma; R Gopal
Journal:  Afr Health Sci       Date:  2013-03       Impact factor: 0.927

8.  Patterns of failure after stereotactic radiotherapy of intracranial meningioma.

Authors:  Vasileios Askoxylakis; Angelika Zabel-du Bois; Wolfgang Schlegel; Jürgen Debus; Peter Huber; Stefanie Milker-Zabel
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

9.  Occupational exposure to magnetic fields and brain tumours in central Sweden.

Authors:  Y Rodvall; A Ahlbom; C Stenlund; S Preston-Martin; T Lindh; B Spännare
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

10.  Large falcine meningioma fed by callosomarginal branch successfully removed following contralateral interhemispheric approach.

Authors:  Ramon F Barajas; Michael E Sughrue; Michael W McDermott
Journal:  J Neurooncol       Date:  2009-08-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.